Pharma News

Tomorrow’s innovations and research are going to be in the cross disciplinary areas and most of the research, innovations and products that are going to come out of engineering are going to be bio-inspired remarked Prof. Anil D.Sahasrabudhe, Chairman, All India Council for Technical Education (AICTE), New Delhi in his inaugural address at the three-day International Conference on “Advances in Pharmaceutical and Health Sciences (ICAPHS - 2020) organised by NGSM Institute of Pharmaceutical Sciences, a constituent college of Nitte(Deemed to be University), Mangalore. He further added, with new technologies like Artificial Intelligence (AI) and Machine learning coming to the fore, it has become mandatory to embed technology into pharmacy, medical, and health sciences education as much as the need to embed biology and biological science in technology education. He said that while our education system has offered CEOs to Google, Microsoft, IBM how could industries in India, not find the right fit of students. Hence there is a need to build an ecosystem of innovation and every institution must have innovation cell he urged.

Acacia Pharma Group plc a hospital pharmaceutical company focused on the development and commercialization of new products aimed at improving the care of patients undergoing significant treatments such as surgery, other invasive procedures, or cancer chemotherapy, announces that the US Food and Drug Administration (FDA) has approved BARHEMSYS® (amisulpride injection) for the prevention and treatment of PONV in adult patients.

Researchers from Trinity College Dublin have made a breakthrough that may eventually lead to improved therapeutic options for people living with asthma. The researchers have uncovered a critical role for a protein (Caspase-11), which had previously never been implicated in the disease.

The nematode roundworm c. elegans. / Gill lab

In a discovery that may further the understanding of diabetes and human longevity, scientists at Scripps Research have found a new biological mechanism of insulin signaling. Their study, involving the roundworm C. elegans, reveals that a “decoy” receptor is at work in binding to insulin molecules and keeping them from sending signals for increased insulin production.

Using a machine-learning algorithm, MIT researchers have identified a powerful new antibiotic compound. In laboratory tests, the drug killed many of the world’s most problematic disease-causing bacteria, including some strains that are resistant to all known antibiotics. It also cleared infections in two different mouse models.

U.S. Food and Drug Administration took additional steps to ensure a smooth regulatory transition aimed at increasing patient access to insulin products used daily by millions of Americans to maintain stable blood glucose levels, as well as certain other biological products set to transition regulatory pathways in March. Today’s actions include publishing a final rule and additional resources to provide useful information to stakeholders, including industry, patients and health care providers.

Maternal obesity may increase a child’s risk for attention-deficit hyperactivity disorder (ADHD), according to an analysis by researchers from the Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD), part of the National Institutes of Health. The researchers found that mothers - but not fathers - who were overweight or obese before pregnancy were more likely to report that their children had been diagnosed with attention-deficit hyperactivity disorder (ADHD) or to have symptoms of hyperactivity, inattentiveness or impulsiveness at ages 7 to 8 years old. Their study appears in The Journal of Pediatrics.

The U.S. Food and Drug Administration  authorized marketing of the first test to detect a genetic condition known as Fragile X Syndrome (FXS), the most common known cause of inherited developmental delay and intellectual disability. The test is intended as an aid in diagnosing FXS and is to be used along with the evaluation of a patient’s family history and clinical signs and symptoms of FXS. Additionally, this test is intended for use in adults who may be carriers of genetic alterations in the gene associated with FXS, called the FMR1 gene.

Novartis announced the European Commission (EC) has approved Beovu® (brolucizumab) injection for the treatment of wet age-related macular degeneration (AMD). Beovu is the first EC-approved anti-VEGF treatment to demonstrate superior resolution of retinal fluid (IRF/SRF), a key marker of disease activity, versus aflibercept (secondary endpoints). Beovu also offers the ability to start eligible wet AMD patients on a three-month dosing interval immediately after the loading phase. The EC decision is applicable to all 27 European Union member states as well as the UK, Iceland, Norway and Liechtenstein.

The U.S. Food and Drug Administration announced that its first bilateral enforcement operation with the Government of India, stopped approximately 500 shipments of illicit, and potentially dangerous, unapproved prescription drugs and combination medical devices from reaching American consumers over the course of an operation that took place in January.